This site is intended for Healthcare Professionals only.

NHS rolls out headache-busting gadget

Date:

Share post:

The NHS has released headache-busting gadget across the country to support patients suffering from cluster headaches.

A small, portable device that can zap away excruciating headaches is now available to anyone who needs it on the NHS.

The gadget is held against the neck and delivers a low-level electric current to block pain signals, relieving pain from people suffering from ‘cluster’ headaches.

NHS England is expanding the use of gammaCore after successful trials held over the last two years.

Around 11,000 people are set to benefit from the device when they have the debilitating headaches.

NHS medical director Stephen Powis said on April 3: “While they may be small, these devices will make a huge difference to people who suffer from these debilitating headaches – relieving painful symptoms and allow people to go about their daily lives as normal.

“The NHS Long Term Plan committed to making cutting edge treatments and technology available to save and improve lives.

“This is the latest example of the NHS testing the latest tech and rolling it out at speed for patients across the country.”

Cluster headaches begin quickly and are often described as a sharp, burning or piercing sensation on one side of the head with attacks lasting between 15 minutes and three hours and occurring up to eight times a day.

Patients can use the device regularly to prevent cluster headaches or when they feel one starting to come on.

Clinicians now have another treatment option for patients, particularly for those who have not had success with other treatments, including triptan – painkillers used to ease migraines and severe headaches.

“The new technology is being made available, as part of the new Medtech Funding Mandate policy, which came into effect on April 1, allowing patients to benefit from fast tracked innovations from the NHS,” the NHS said.

About one to two people in every 1,000 are affected by the rare type of headache and around one in 20 do not respond to traditional methods, including painkillers or oxygen.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Natural wellness brand Brown’s CBD reveals UK’s top CBD hotspots: Dundee ranks no.1

Cannabidiol (CBD) is one of the non-psychoactive compounds found in cannabis which has garnered widespread curiosity over the...

‘Community pharmacies at risk of layoffs and service reductions without funding boost’, says NPA

Suggests a 2.5 per cent of the NHS budget to restore community pharmacy funding  The National Pharmacy Association (NPA)...

Dental and pharmacy technicians to free up appointments; get more power to supply meds

25,500 pharmacy technicians, 9,733 dental hygienists and 6,198 dental therapists in the UK to benefit from the new...

RPS assembly advances strategic reforms for enhanced professional leadership

RPS to facilitate a "more accessible nomination process" and "advocate for deserving recognition of pharmacists and allied professionals" In...